Prevalence and clinical correlates of bronchoreversibility in severe emphysema

M. K. Han, Robert A Wise, J. Mumford, F. Sciurba, G. J. Criner, J. L. Curtis, S. Murray, Alice L Sternberg, G. Weinman, E. Kazerooni, A. P. Fishman, B. Make, E. A. Hoffman, Z. Mosenifar, F. J. Martinez

Research output: Contribution to journalArticle

Abstract

Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility. 544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV1) in this patient population is 24% predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64% of patients demonstrated large (≥400 mL) changes in forced vital capacity (FVC). In a severe emphysema population, bronchoreversibility as defined by change in FEV1 is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients. Copyright

Original languageEnglish (US)
Pages (from-to)1048-1056
Number of pages9
JournalEuropean Respiratory Journal
Volume35
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Emphysema
Vital Capacity
Forced Expiratory Volume
Chronic Obstructive Pulmonary Disease
Population
Tomography
Quality of Life
Phenotype
Lung

Keywords

  • Bronchodilator
  • Chronic obstructive pulmonary disease
  • Computed tomography
  • Emphysema

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Han, M. K., Wise, R. A., Mumford, J., Sciurba, F., Criner, G. J., Curtis, J. L., ... Martinez, F. J. (2010). Prevalence and clinical correlates of bronchoreversibility in severe emphysema. European Respiratory Journal, 35(5), 1048-1056. https://doi.org/10.1183/09031936.00052509

Prevalence and clinical correlates of bronchoreversibility in severe emphysema. / Han, M. K.; Wise, Robert A; Mumford, J.; Sciurba, F.; Criner, G. J.; Curtis, J. L.; Murray, S.; Sternberg, Alice L; Weinman, G.; Kazerooni, E.; Fishman, A. P.; Make, B.; Hoffman, E. A.; Mosenifar, Z.; Martinez, F. J.

In: European Respiratory Journal, Vol. 35, No. 5, 05.2010, p. 1048-1056.

Research output: Contribution to journalArticle

Han, MK, Wise, RA, Mumford, J, Sciurba, F, Criner, GJ, Curtis, JL, Murray, S, Sternberg, AL, Weinman, G, Kazerooni, E, Fishman, AP, Make, B, Hoffman, EA, Mosenifar, Z & Martinez, FJ 2010, 'Prevalence and clinical correlates of bronchoreversibility in severe emphysema', European Respiratory Journal, vol. 35, no. 5, pp. 1048-1056. https://doi.org/10.1183/09031936.00052509
Han, M. K. ; Wise, Robert A ; Mumford, J. ; Sciurba, F. ; Criner, G. J. ; Curtis, J. L. ; Murray, S. ; Sternberg, Alice L ; Weinman, G. ; Kazerooni, E. ; Fishman, A. P. ; Make, B. ; Hoffman, E. A. ; Mosenifar, Z. ; Martinez, F. J. / Prevalence and clinical correlates of bronchoreversibility in severe emphysema. In: European Respiratory Journal. 2010 ; Vol. 35, No. 5. pp. 1048-1056.
@article{bbb4d8eaa14b4ac784dcb8a967fa0a64,
title = "Prevalence and clinical correlates of bronchoreversibility in severe emphysema",
abstract = "Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility. 544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV1) in this patient population is 24{\%} predicted. 22.2{\%} of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37{\%}) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64{\%} of patients demonstrated large (≥400 mL) changes in forced vital capacity (FVC). In a severe emphysema population, bronchoreversibility as defined by change in FEV1 is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients. Copyright",
keywords = "Bronchodilator, Chronic obstructive pulmonary disease, Computed tomography, Emphysema",
author = "Han, {M. K.} and Wise, {Robert A} and J. Mumford and F. Sciurba and Criner, {G. J.} and Curtis, {J. L.} and S. Murray and Sternberg, {Alice L} and G. Weinman and E. Kazerooni and Fishman, {A. P.} and B. Make and Hoffman, {E. A.} and Z. Mosenifar and Martinez, {F. J.}",
year = "2010",
month = "5",
doi = "10.1183/09031936.00052509",
language = "English (US)",
volume = "35",
pages = "1048--1056",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

TY - JOUR

T1 - Prevalence and clinical correlates of bronchoreversibility in severe emphysema

AU - Han, M. K.

AU - Wise, Robert A

AU - Mumford, J.

AU - Sciurba, F.

AU - Criner, G. J.

AU - Curtis, J. L.

AU - Murray, S.

AU - Sternberg, Alice L

AU - Weinman, G.

AU - Kazerooni, E.

AU - Fishman, A. P.

AU - Make, B.

AU - Hoffman, E. A.

AU - Mosenifar, Z.

AU - Martinez, F. J.

PY - 2010/5

Y1 - 2010/5

N2 - Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility. 544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV1) in this patient population is 24% predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64% of patients demonstrated large (≥400 mL) changes in forced vital capacity (FVC). In a severe emphysema population, bronchoreversibility as defined by change in FEV1 is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients. Copyright

AB - Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility. 544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV1) in this patient population is 24% predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64% of patients demonstrated large (≥400 mL) changes in forced vital capacity (FVC). In a severe emphysema population, bronchoreversibility as defined by change in FEV1 is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients. Copyright

KW - Bronchodilator

KW - Chronic obstructive pulmonary disease

KW - Computed tomography

KW - Emphysema

UR - http://www.scopus.com/inward/record.url?scp=77951950812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951950812&partnerID=8YFLogxK

U2 - 10.1183/09031936.00052509

DO - 10.1183/09031936.00052509

M3 - Article

VL - 35

SP - 1048

EP - 1056

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 5

ER -